Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics

The global oligonucleotide therapeutics market is projected to grow from USD 7.7 billion in 2025 to USD 72.1 billion by 2035, expanding at a 23.4% CAGR. Growth is driven by advances in RNA-based medicine, targeted delivery technologies, expanding applications beyond rare diseases into chronic and metabolic conditions, and increasing regulatory approvals. Antisense oligonucleotides lead the market at 39.9% share, while subcutaneous administration dominates at 56.4%. North America commands 57.9% market share.

09/15/2026, 5:58 AM • GlobeNewswire

Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight

The metastatic prostate cancer market is projected to experience robust growth through 2036, valued at USD 11.5 billion in 2025 across seven major markets. The market is transitioning from conventional androgen deprivation therapy toward combination-based, biomarker-driven approaches, with novel therapies such as PSMA-targeted radioligand therapies and PARP inhibitors reshaping the treatment paradigm. Key emerging drugs include 225Ac-PSMA-617, 177Lu-DOTA-rosopatamab, and cabozantinib, with multiple pharmaceutical companies advancing innovative treatments in clinical trials.

06/10/2026, 1:00 PM • GlobeNewswire

Tacrolimus Market Research Report 2026: Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2035

The global tacrolimus market is projected to grow from USD 7.3 billion in 2025 to USD 12.7 billion by 2035 at a CAGR of 5.6%, driven by rising organ transplant procedures and increasing autoimmune disease prevalence. Injectable formulations and hospital settings dominate the market, with North America accounting for 40.4% of the market share. Key players are investing in R&D for improved formulations and expanding into emerging markets.

05/25/2026, 5:31 AM • GlobeNewswire

Oncolytic Virus Immunotherapy Market Landscape Report 2026: A $5 Opportunity by 2031 - Technology Platforms, Approved Therapy Dosage, Price & Clinical Trials Insights

The global oncolytic virus immunotherapy market is projected to reach over $5 billion by 2031, with three approved therapies and more than 150 candidates in clinical trials. Major pharmaceutical companies and biotechnology firms are advancing combination therapies and strategic partnerships to address cancer treatment challenges, with significant clinical development underway across multiple indications.

04/21/2026, 4:14 AM • GlobeNewswire

Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026

Sutro Biopharma announced promising preclinical data for its ADC pipeline at AACR 2026, with STRO-004 demonstrating robust antitumor activity across multiple solid tumor models and improved efficacy versus benchmark ADCs. The company also presented data for STRO-006 and STRO-227, with IND submissions planned for 2026. Partner Astellas presented results from ASP2998, a TROP2-targeted immunostimulatory ADC that entered clinical trials earlier in 2026.

04/19/2026, 7:45 PM • GlobeNewswire

$5.14 Bn Castration-sensitive Prostate Cancer Market Insights, Epidemiology, and Forecasts, 2022-2026 & 2026-2036

The castration-sensitive prostate cancer (CSPC) market is expected to grow significantly from $5.14 billion in 2025 to $11.75 billion by 2036, driven by an aging population, increased disease awareness, and successive drug approvals. Key therapies like XTANDI and ERLEADA are dominating the market, while newer treatments including PARP inhibitors and radioligand therapies are emerging. Recent approvals and expanded labels for existing drugs are accelerating market growth across major regions.

04/13/2026, 4:44 AM • GlobeNewswire

Vir Biotechnology (VIR) CEO Sells 73,000 Shares for $664,000

Vir Biotechnology CEO Marianne De Backer sold 72,559 shares worth $664,350 on April 6, 2026, representing 6.76% of her holdings. The sale aligns with her historical selling patterns and appears to be income supplementation rather than a loss of confidence. The company has shown positive momentum with encouraging clinical trial results for VIR-5500 and a significant partnership deal with Astellas Pharma worth $315 million.

04/12/2026, 9:13 AM • The Motley Fool

4D Path Joins Phase II Clinical Trial to Advance Predictive Biomarkers in Bladder Cancer

4D Path announced its participation as an exploratory biomarker collaborator in the Phase II DAD-IO clinical study led by Dana-Farber Cancer Institute and supported by Gilead Sciences. The study evaluates a novel combination therapy using two Antibody Drug Conjugates (Sacituzumab Govitecan and Enfortumab Vedotin) with or without Pembrolizumab for patients with locally advanced or metastatic urothelial carcinoma. 4D Path will use its proprietary QPOR platform to analyze pre-treatment biopsy slides to predict patient response to therapy.

01/22/2026, 12:00 PM • GlobeNewswire

Geographic Atrophy Market to Surge Significantly During the Forecast Period (2025–2034) Due to Rising Adoption of Complement Inhibitor Therapies | DelveInsight

The geographic atrophy market is expected to grow significantly due to rising global prevalence, aging populations, and emerging therapies targeting this advanced form of age-related macular degeneration.

12/01/2025, 1:00 PM • GlobeNewswire

CytomX Therapeutics to Present at the Jefferies London Healthcare Conference

CytomX Therapeutics, a clinical-stage oncology-focused biopharmaceutical company, announced upcoming presentations of its clinical-stage pipeline including CX-2051 and CX-801, with Phase 1 data updates expected in early 2026.

11/13/2025, 8:00 AM • GlobeNewswire

Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day

Sutro Biopharma announced the initiation of its Phase 1 study for STRO-004, a Tissue Factor ADC, and selected PTK7 as the target for its first dual-payload candidate STRO-227, showcasing its innovative antibody-drug conjugate platform.

11/12/2025, 10:00 AM • GlobeNewswire

CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025

CytomX Therapeutics will report its third quarter financial results on November 6, 2025, after market close, followed by a conference call and webcast at 5:00 p.m. ET.

10/30/2025, 8:00 AM • GlobeNewswire

Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients

Merck, in collaboration with Pfizer and Astellas Pharma, announced successful Phase 3 trial results for Keytruda-Padcev combination therapy in muscle-invasive bladder cancer patients, showing significant improvements in survival outcomes.

08/12/2025, 10:46 AM • Benzinga